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Early phase II study of interferon-alpha and
tumor necrosis factor-alpha combination in
patients with advanced cancer.∗
Kunzo Orita, Sadanori Fuchimoto, Masashi Kurimoto, Shunsaku Ando, and Jun
Minowada
Abstract
Synergistic enhancement of anti-tumor effects through the combined use of natural human
interferon-alpha (nHuIFN-alpha) and natural human tumor necrosis factor-alpha (nHuTNF-alpha)
enabled us to decrease the effective dose of each cytokine and consequently to reduce side ef-
fects. One hundred and twenty patients with advanced or recurrent solid cancer were entered in
the trial from April 1985 to January 1988, of whom 112 patients were evaluable. A mixture of
nHuINF-alpha and nHuTNF-alpha was injected intravenously as the maintenance dose 1 x 10(6)U
or more/day for over 8 weeks. There was no response in 40 patients injected with the maintenance
dose of 1 x 10(6)U/day, but of 72 patients receiving more than 2 x 10(6)U/day (10 micrograms
of nHuIFN-alpha and 3 micrograms of nHuTNF-alpha), 4 had complete responses, 10 had partial
responses, and 4 had minor responses. The overall response rate was 12.5% (14/112) and the rate
was 19.5% in 72 patients with more than 2 x 10(6)U/day. Positive responses were as follows: hep-
atoma 3/8), renal cell cancer (4/11), breast cancer (4/17), ovarian cancer (1/2), malignant thymoma
(1/1) and liposarcoma (1/1). Serious adverse effects like hypotension, oliguria and severe hepato-
biliary toxicity were never experienced. The effective and adequate dose of the mixed preparation
was considered 2 to 4 x 10(6)U/day/body.
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